Abcam and BrickBio Announce a Partnership to Incorporate Conjugation-Ready Sites into Recombinant Antibodies Across Abcam’s Portfolio
BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites Together, the organizations will industrialize the technology to serve both the research and diagnostic markets CAMBRIDGE, UK and BOSTON, MA, USA, November 08, 2019 / B3C newswire / — Abcam plc, a global innovator in life science reagents and tools, is today pleased... Read more